Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/novel-therapeutic-strategies-in-adult-acute-lymphoblastic-leukemia-a-CgnCvMLLMj
References (111)
-
R. Kreitman, M. Tallman, S. Coutre, T. Robak, W. Wilson, M. Stetler-Stevenson, P. Noel, D. FitzGerald, Manuela Buzoianu, R. Lechleider, I. Pastan (2010)
A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated ResultsBlood, 116
-
M. Dworzak, A. Schumich, D. Printz, U. Pötschger, Z. Husak, A. Attarbaschi, G. Basso, G. Gaipa, R. Ratei, G. Mann, H. Gadner (2008)
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.Blood, 112 10
-
J. Teeling, W. Mackus, L. Wiegman, J. Brakel, S. Beers, R. French, T. Meerten, S. Ebeling, T. Vink, J. Slootstra, P. Parren, M. Glennie, J. Winkel (2006)
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201The Journal of Immunology, 177
-
T. Robak, A. Dmoszyńska, P. Solal-Céligny, K. Warzocha, J. Loscertales, J. Catalano, B. Afanasiev, L. Larratt, C. Geisler, M. Montillo, Ilya Zyuzgin, P. Ganly, C. Dartigeas, A. Rosta, Jörg Maurer, M. Mendila, M. Saville, N. Valente, M. Wenger, S. Moiseev (2010)
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 10
-
M. Topp, N. Gökbuget, G. Zugmaier, E. Degenhard, M. Goebeler, M. Klinger, S. Neumann, H. Horst, T. Raff, A. Viardot, M. Stelljes, M. Schaich, R. Köhne-Volland, M. Brüggemann, O. Ottmann, T. Burmeister, P. Baeuerle, D. Nagorsen, Margit Schmidt, H. Einsele, G. Riethmüller, M. Kneba, D. Hoelzer, P. Kufer, R. Bargou (2012)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.Blood, 120 26
-
D Pulte, A Gondos, H Brenner (2009)
Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st centuryBlood, 113
-
D. Maloney (2001)
Mechanism of action of rituximab.Anti-cancer drugs, 12 Suppl 2
-
J. Rowe, G. Buck, A. Burnett, R. Chopra, P. Wiernik, S. Richards, H. Lazarus, I. Franklin, M. Litzow, N. Ciobanu, H. Prentice, J. Durrant, M. Tallman, A. Goldstone (2005)
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.Blood, 106 12
-
E. Raetz, M. Cairo, M. Borowitz, S. Blaney, M. Krailo, T. Leil, J. Reid, D. Goldenberg, W. Wegener, W. Carroll, P. Adamson (2008)
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 22
-
MS Topp, N Goekbuget, P Kufer (2009)
Blinatumomab (anti-Cd19 Bite?) for targeted therapy of minimal residual disease (Mrd) in Patients with B precursor acute lymphoblastic leukemia (All): Update of an ongoing Phase II studyHaematol-Hematol J, 94
-
R. Bassan, D. Hoelzer (2011)
Modern therapy of acute lymphoblastic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 5
-
A. Jemal, R. Siegel, Elizabeth Ward, Taylor Murray, Jiaquan Xu, Carol Smigal, M. Thun (2006)
Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 56
-
Martin Dyer, Geoff Hale, F. Hayhoe, H. Waldmann (1989)
Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.Blood, 73 6
-
D. Thomas, S. O'brien, H. Kantarjian (2009)
Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.Hematology/oncology clinics of North America, 23 5
-
G. Gaipa, G. Basso, R. Ratei, A. Biondi, M. Dworzak (2005)
Reply to van der Sluijs-Gelling et alLeukemia, 19
-
C. Deng (2011)
Chemoimmunotherapy with A Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic LeukemiaJournal of Evidence-based Medicine
-
L Vidal, A Gafter-Gvili, G Salles (2011)
Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trialsJ Natl Cancer Inst, 103
-
A. Kentsis, T. Sanda, V. Ngo, S. Rodig, J. Kutok, E. Tholouli, R. Byers, G. Woude, A. Kung, L. Staudt, A. Look (2010)
Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia.Blood, 116
-
B. Cheson (2010)
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 21
-
D. Thomas, S. O'brien, J. Jorgensen, J. Cortes, S. Faderl, G. Garcia-Manero, S. Verstovsek, C. Koller, S. Pierce, Y. Huh, W. Wierda, M. Keating, H. Kantarjian (2009)
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.Blood, 113 25
-
J. Carnahan, Paul Wang, R. Kendall, Ching Chen, Sylvia Hu, T. Boone, T. Juan, J. Talvenheimo, S. Montestruque, Jilin Sun, G. Elliott, John Thomas, J. Ferbas, B. Kern, R. Briddell, J. Leonard, A. Cesano (2003)
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 10 Pt 2
-
D. Hoelzer, A. Huettmann, F. Kaul, S. Irmer, N. Jaekel, M. Mohren, T. Lipp, Knut Wedelin, Francisco Valle, M. Schmid, E. Thiel, M. Brueggemann, M. Kneba, N. Goekbuget (2010)
Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003Blood, 116
-
A. Younes, L. Gordon, Stella Kim, J. Romaguera, A. Copeland, Silvana Farial, L. Kwak, L. Fayad, F. Hagemeister, M. Fanale, J. Lambert, T. Bagulho, R. Morariu-Zamfir (2009)
Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).Blood, 114
-
Raymond Cruz, F. Hernandez-Ilizaliturri, S. Olejniczak, G. Deeb, J. Knight, P. Wallace, B. Thurberg, William Kennedy, M. Czuczman (2007)
CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphomaLeukemia & Lymphoma, 48
-
A. Pession, M. Valsecchi, G. Masera, W. Kamps, E. Magyarosy, C. Rizzari, E. Wering, L. Nigro, A. Does, F. Locatelli, G. Basso, M. Aricò (2005)
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 28
-
R. Arceci (2009)
Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st centuryYearbook of Oncology, 2009
-
J. Carnahan, R. Stein, Z. Qu, Kristen Hess, A. Cesano, H. Hansen, D. Goldenberg (2007)
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.Molecular immunology, 44 6
-
P. Gaynon, M. Trigg, N. Heerema, M. Sensel, H. Sather, G. Hammond, W. Bleyer (2000)
Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995Leukemia, 14
-
R. Larson (2004)
The U.S. trials in adult acute lymphoblastic leukemia.Annals of hematology, 83 Suppl 1
-
C. Pui, W. Carroll, S. Meshinchi, R. Arceci (2011)
Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 5
-
K. Parmar, P. Vinciguerra, S. Godinho, A. Hamilton, D. Pellman, A. D’Andrea (2010)
Cytokinesis Failure In Fanconi Anemia Pathway Deficient Hematopoietic CellsBlood, 116
-
E. Raetz, M. Cairo, M. Borowitz, Xiaomin Lu, M. Devidas, J. Reid, D. Goldenberg, W. Wegener, J. Whitlock, P. Adamson, S. Hunger, W. Carroll (2011)
Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2Blood, 118
-
R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, S. Knop, R. Noppeney, A. Viardot, G. Hess, M. Schuler, H. Einsele, C. Brandl, A. Wolf, P. Kirchinger, Petra Klappers, Margit Schmidt, G. Riethmüller, C. Reinhardt, P. Baeuerle, P. Kufer (2008)
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging AntibodyScience, 321
-
G. Salvatore, R. Beers, I. Margulies, R. Kreitman, I. Pastan (2002)
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 4
-
S. Maury, F. Huguet, T. Leguay, F. Lacombe, M. Maynadie, S. Girard, A. Labarthe, E. Kuhlein, E. Raffoux, X. Thomas, P. Chevallier, A. Buzyn, A. Delannoy, Y. Chalandon, J. Vernant, P. Rousselot, E. Macintyre, N. Ifrah, H. Dombret, M. Béné (2010)
Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemiaHaematologica, 95
-
L. Annino, M. Vegna, A. Camera, G. Specchia, G. Visani, G. Fioritoni, F. Ferrara, A. Peta, S. Ciolli, W. Deplano, F. Fabbiano, S. Sica, F. Raimondo, N. Cascavilla, A. Tabilio, P. Leoni, R. Invernizzi, M. Baccarani, B. Rotoli, S. Amadori, F. Mandelli (2002)
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.Blood, 99 3
-
W. Heit, D. Bunjes, M. Wiesneth, T. Schmeiser, R. Arnold, G. Hale, H. Waldmann, H. Heimpel (1986)
Ex vivo T‐cell depletion with the monoclonal antibody Campath‐1 plus human complement effectively prevents acute graft‐versus‐host disease in allogeneic bone marrow transplantationBritish Journal of Haematology, 64
-
A. Ricart (2011)
Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab OzogamicinClinical Cancer Research, 17
-
John Weldon, Laiman Xiang, O. Chertov, I. Margulies, R. Kreitman, D. FitzGerald, I. Pastan (2009)
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.Blood, 113 16
-
S. Branford, D. Yeung, Jodi Prime, D. Ross, T. Hughes (2011)
Imatinib Dose Interruption in Responding CML Patients Is Associated with Characteristic BCR-ABL Kinetics, Which Could Help to Differentiate Non-Adherence From Drug ResistanceBlood, 118
-
M. Aricò, M. Valsecchi, B. Camitta, M. Schrappe, J. Chessells, A. Baruchel, P. Gaynon, L. Silverman, G. Janka-Schaub, W. Kamps, Pui Ch, G. Masera (2000)
Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.The New England journal of medicine, 342 14
-
W. Stock, B. Sanford, G. Lozanski, R. Vij, J. Byrd, B. Powell, M. Wetzler, D. Sher, C. Edwards, M. Kelly, S. Richards, Crystal Sung, G. Malnassy, E. Hoke, C. Bloomfield, R. Larson (2009)
Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).Blood, 114
-
G. Raskob, A. Gallus, G. Pineo, Dalei Chen, L. Ramirez, M. Lassen (2010)
Apixaban Versus Enoxaparin for Thromboprophylaxis After Joint Replacement Surgery: Pooled Analysis of Major Venous Thromboembolism and Bleeding In 8,464 Patients From the ADVANCE 2 and 3 TrialsBlood, 116
-
W. Wierda, T. Kipps, J. Mayer, S. Stilgenbauer, C. Williams, A. Hellmann, T. Robak, R. Furman, P. Hillmen, M. Trněný, M. Dyer, S. Padmanabhan, M. Piotrowska, T. Kozák, G. Chan, Randy Davis, N. Losic, J. Wilms, C. Russell, A. Osterborg (2010)
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 10
-
N. Thawani, M. Tam, M. Stevenson (2009)
STAT6-mediated suppression of erythropoiesis in an experimental model of malarial anemiaHaematologica, 94
-
H. Kantarjian, D. Thomas, A. Wayne, S. O'brien (2012)
Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 31
-
M. Topp, N. Goekbuget, G. Zugmaier, A. Viardot, M. Stelljes, S. Neumann, H. Horst, A. Reichle, R. Marks, M. Brueggemann, M. Ritgen, Petra Klappers, Noemi Mergen, M. Goebeler, H. Einsele, D. Hoelzer, R. Bargou (2011)
Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II TrialBlood, 118
-
A. Angiolillo, A. Yu, G. Reaman, A. Ingle, R. Secola, P. Adamson (2009)
A phase II study of Campath‐1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group reportPediatric Blood & Cancer, 53
-
J. Leonard, M. Coleman, Jamie Ketas, A. Chadburn, S. Ely, R. Furman, W. Wegener, H. Hansen, Heather Ziccardi, M. Eschenberg, U. Gayko, A. Cesano, D. Goldenberg (2003)
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 16
-
N. Gokbuget, D. Hoelzer, R. Arnold, A. Böhme, C. Bartram, M. Freund, A. Ganser, M. Kneba, W. Langer, T. Lipp, W. Ludwig, G. Maschmeyer, H. Rieder, E. Thiel, A. Weiss, D. Messerer (2000)
Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).Hematology/oncology clinics of North America, 14 6
-
J. Storring, M. Minden, Susan Kao, Vikas Gupta, A. Schuh, A. Schimmer, K. Yee, S. Kamel‐Reid, Hong Chang, J. Lipton, H. Messner, W. Xu, J. Brandwein (2009)
Treatment of adults with BCR‐ABL negative acute lymphoblastic leukaemia with a modified paediatric regimenBritish Journal of Haematology, 146
-
M. Dworzak, G. Gaipa, A. Schumich, O. Maglia, R. Ratei, M. Veltroni, Z. Husak, G. Basso, L. Karawajew, H. Gadner, A. Biondi (2010)
Modulation of antigen expression in B‐cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug‐induced regulatory phenomenon. Results of the AIEOP‐BFM‐ALL‐FLOW‐MRD‐Study GroupCytometry Part B: Clinical Cytometry, 78B
-
Bo-hua Li, Lei Zhao, Huaizu Guo, Chong Wang, Xunming Zhang, Lan Wu, Lin Chen, Qing Tong, Wei-zhu Qian, Hao Wang, Ya-jun Guo (2009)
Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma.Blood, 114 24
-
W. Rowan, J. Tite, P. Topley, S. Brett (1998)
Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cellsImmunology, 95
-
B. Oiffier, E. Epage, J. Rière, R. Erbrecht, T. Illy, R. Ouabdallah, P. Ierre, M. Orel, E. Este, G. Alles, P. Aulard, F. Eyes, C. Isselbrecht (2002)
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaThe New England Journal of Medicine, 346
-
M. Gilleece, T. Dexter (1993)
Effect of Campath-1H antibody on human hematopoietic progenitors in vitro.Blood, 82 3
-
J. Teeling, R. French, M. Cragg, J. Brakel, M. Pluyter, Haichun Huang, C. Chan, P. Parren, C. Hack, M. Dechant, T. Valerius, J. Winkel, M. Glennie (2004)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.Blood, 104 6
-
S. O'brien, D. Thomas, F. Ravandi, S. Faderl, S. Pierce, H. Kantarjian (2008)
Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemiaCancer, 113
-
N. Gökbuget, D. Hoelzer (2006)
Novel antibody-based therapy for acute lymphoblastic leukaemia.Best practice & research. Clinical haematology, 19 4
-
L. Ginaldi, M. Martinis, E. Matutes, N. Farahat, R. Morilla, D. Catovsky (1998)
Levels of expression of CD19 and CD20 in chronic B cell leukaemias.Journal of Clinical Pathology, 51
-
G. Gaipa, G. Basso, O. Maglia, V. Leoni, A. Faini, G. Cazzaniga, C. Bugarin, M. Veltroni, B. Michelotto, R. Ratei, T. Coliva, M. Valsecchi, A. Biondi, M. Dworzak (2005)
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detectionLeukemia, 19
-
Rupert Handgretinger, G. Zugmaier, G. Henze, H. Kreyenberg, P. Lang, A. Stackelberg (2011)
Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemiaLeukemia, 25
-
H. Kantarjian, D. Thomas, S. O'brien, J. Cortes, F. Giles, S. Jeha, C. Bueso-Ramos, S. Pierce, J. Shan, C. Koller, M. Beran, M. Keating, E. Freireich (2004)
Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemiaCancer, 101
-
CH Pui, WE Evans (1998)
Acute lymphoblastic leukemiaN Engl J Med, 339
-
A. Treumann, M. Lifely, P. Schneider, M. Ferguson (1995)
Primary Structure of CD52 (*)The Journal of Biological Chemistry, 270
-
T. Watt, Sunita Park, T. Cooper (2010)
CD20 up-Regulation In Induction Therapy for Childhood B Lymphoblastic LeukemiaBlood, 116
-
A. Jazirehi, M. Vega, B. Bonavida (2007)
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.Cancer research, 67 3
-
S. Raponi, Maria Propris, S. Intoppa, Maria Milani, A. Vitale, L. Elia, O. Perbellini, G. Pizzolo, R. Foà, A. Guarini (2011)
Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeukemia & Lymphoma, 52
-
P. Piccaluga, M. Arpinati, A. Candoni, C. Laterza, S. Paolini, A. Gazzola, E. Sabattini, G. Visani, S. Pileri (2011)
Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemiaLeukemia & Lymphoma, 52
-
J. Alvarnas, P. Brown, P. Aoun, K. Ballen, Naresh Bellam, W. Blum, M. Boyer, H. Carraway, P. Coccia, S. Coutre, J. Cultrera, L. Damon, D. DeAngelo, D. Douer, H. Frangoul, O. Frankfurt, S. Goorha, M. Millenson, S. O'brien, S. Petersdorf, A. Rao, S. Terezakis, G. Uy, M. Wetzler, A. Zelenetz, M. Naganuma, K. Gregory (2019)
Acute lymphoblastic leukemia.Journal of the National Comprehensive Cancer Network : JNCCN, 10 7
-
A. Wayne, D. Bhojwani, L. Silverman, Kelly Richards, M. Stetler-Stevenson, N. Shah, S. Jeha, C. Pui, Manuela Buzoianu, D. FitzGerald, R. Kreitman, R. Ibrahim, I. Pastan (2011)
A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)Blood, 118
-
H. Kantarjian, S. O'brien, T. Smith, J. Cortes, F. Giles, M. Beran, S. Pierce, Y. Huh, M. Andreeff, C. Koller, C. Ha, M. Keating, S. Murphy, E. Freireich (2000)
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 3
-
D. Hoelzer, N. Gökbuget (2012)
Chemoimmunotherapy in acute lymphoblastic leukemia.Blood reviews, 26 1
-
DA Thomas, S O'Brien, S Faderl (2010)
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaJournal of clinical oncology: official journal of the American Society of Clinical Oncology, 28
-
M. Topp, Nikola Goekbuget, P. Kufer, G. Zugmaier, E. Degenhard, S. Neumann, H. Horst, A. Viardot, M. Schmid, O. Ottmann, Margit Schmidt, C. Reinhardt, P. Baeuerle, D. Nagorsen, D. Hoelzer, R. Bargou (2008)
Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.Blood, 112
-
R. Kreitman, W. Wilson, K. Bergeron, Miranda Raggio, M. Stetler-Stevenson, D. FitzGerald, I. Pastan (2001)
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.The New England journal of medicine, 345 4
-
A. Advani, B. Coiffier, M. Czuczman, M. Dreyling, J. Foran, E. Giné, C. Gisselbrecht, N. Ketterer, S. Nasta, A. Rohatiner, I. Schmidt-Wolf, M. Schuler, J. Sierra, Mitchell Smith, G. Verhoef, J. Winter, J. Boni, E. Vandendries, M. Shapiro, L. Fayad (2010)
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 12
-
Hong-lin Xu, Jun Yan, Ziqiang Zhu, Yiming Huang, Y. Wen, L. Bozulic, S. Ildstad (2010)
A Critical Role for Innate Immunity In Allogeneic Hematopoietic Cell Rejection Via the TLR4/TRIF PathwayBlood, 116
-
S Faderl, S O'Brien, CH Pui (2010)
Adult acute lymphoblastic leukemia: concepts and strategiesCancer, 116
-
A. Wayne, R. Kreitman, H. Findley, Glen Lew, Cindy Delbrook, S. Steinberg, M. Stetler-Stevenson, D. FitzGerald, I. Pastan (2010)
Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical TrialClinical Cancer Research, 16
-
N. Gökbuget, D. Hoelzer (2004)
Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospectsAnnals of Hematology, 83
-
D. Thomas, S. Faderl, S. O'brien, C. Bueso-Ramos, J. Cortes, G. Garcia-Manero, F. Giles, S. Verstovsek, W. Wierda, S. Pierce, J. Shan, M. Brandt, F. Hagemeister, M. Keating, F. Cabanillas, H. Kantarjian (2006)
Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemiaCancer, 106
-
H. Kantarjian, D. Thomas, J. Jorgensen, E. Jabbour, P. Kebriaei, M. Rytting, S. York, F. Ravandi, M. Kwari, S. Faderl, M. Rios, J. Cortes, L. Fayad, R. Tarnai, Sa Wang, R. Champlin, A. Advani, S. O'brien (2012)
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.The Lancet. Oncology, 13 4
-
R. Kreitman, David Squires, M. Stetler-Stevenson, P. Noel, D. FitzGerald, W. Wilson, I. Pastan (2005)
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 27
-
G. Salles, J. Seymour, F. Offner, A. López-Guillermo, D. Belada, L. Xerri, P. Feugier, R. Bouabdallah, J. Catalano, P. Brice, D. Caballero, C. Haioun, L. Pedersen, A. Delmer, D. Simpson, S. Leppa, P. Soubeyran, A. Hagenbeek, O. Casasnovas, T. Intragumtornchai, C. Fermé, Maria Silva, C. Sebban, A. Lister, J. Estell, G. Milone, A. Sonet, M. Mendila, B. Coiffier, H. Tilly (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trialThe Lancet, 377
-
A. Polson, W. Ho, V. Ramakrishnan (2011)
Investigational antibody-drug conjugates for hematological malignanciesExpert Opinion on Investigational Drugs, 20
-
A. Goy, J. Leach, W. Ehmann, K. Ando, K. Hatake, K. Tobinai, T. Feldman, S. Hua, A. Volkert, E. Vandendries, M. Ogura (2010)
Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 TrialBlood, 116
-
R. Tibes, M. Keating, A. Ferrajoli, W. Wierda, F. Ravandi, G. Garcia-Manero, S. O'brien, J. Cortes, S. Verstovsek, M. Browning, S. Faderl (2006)
Activity of alemtuzumab in patients with CD52‐positive acute leukemiaCancer, 106
-
V. Blanc, A. Bousseau, A. Caron, C. Carrez, R. Lutz, J. Lambert (2011)
SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell MalignanciesClinical Cancer Research, 17
-
M. Hallek, K. Fischer, G. Fingerle-Rowson, A. Fink, R. Busch, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. Grünhagen, Matthias Bergmann, J. Catalano, P. Zinzani, F. Caligaris‐cappio, J. Seymour, A. Berrebi, U. Jäger, B. Cazin, M. Trněný, A. Westermann, C. Wendtner, B. Eichhorst, P. Staib, A. Bühler, D. Winkler, T. Zenz, S. Böttcher, M. Ritgen, M. Mendila, M. Kneba, H. Döhner, S. Stilgenbauer (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 376
-
F. Huguet, T. Leguay, E. Raffoux, X. Thomas, K. Beldjord, E. Delabesse, P. Chevallier, A. Buzyn, A. Delannoy, Y. Chalandon, J. Vernant, M. Lafage-Pochitaloff, A. Chassevent, V. Lheritier, E. Macintyre, M. Béné, N. Ifrah, H. Dombret (2009)
Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 6
-
Frank Cichocki, T. Lenvik, S. Anderson, Jeffrey Miller (2008)
Antisense transcripts negatively regulate transcription of multiple variegated killer immunoglobulin-like receptor (KIR) genes (136.38)The Journal of Immunology
-
M. Hunault, J. Harousseau, M. Delain, M. Truchan-Graczyk, J. Cahn, F. Witz, T. Lamy, B. Pignon, J. Jouet, R. Garidi, D. Caillot, C. Berthou, D. Guyotat, A. Sadoun, J. Sotto, B. Lioure, P. Casassus, P. Solal-Céligny, L. Stalnikiewicz, B. Audhuy, O. Blanchet, L. Baranger, M. Béné, N. Ifrah (2004)
Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial.Blood, 104 10
-
S. Ntoufa, A. Vardi, N. Papakonstantinou, A. Anagnostopoulos, V. Aleporou‐Marinou, F. Caligaris‐cappio, C. Belessi, P. Ghia, M. Muzio, K. Stamatopoulos (2010)
Differential Functional Outcomes After Stimulation Via Innate Immunity Receptors In Chronic Lymphocytic Leukemia Subtypes Defined by the Molecular Features of the Immunoglobulin ReceptorBlood, 116
-
C. Pui, Leslie Robison, A. Look (2008)
Acute lymphoblastic leukaemiaThe Lancet, 371
-
A. Al-Katib, A. Aboukameel, R. Mohammad, M. Bissery, C. Zuany‐Amorim (2009)
Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's LymphomaClinical Cancer Research, 15
-
P. Hillmen, A. Skotnicki, T. Robak, B. Jakšić, A. Dmoszyńska, Jingyang Wu, C. Sirard, J. Mayer (2007)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 35
-
M. Keating, I. Flinn, V. Jain, J. Binet, P. Hillmen, J. Byrd, M. Albitar, L. Brettman, P. Santabarbara, B. Wacker, K. Rai (2002)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.Blood, 99 10
-
S. Faderl, S. O'brien, C. Pui, W. Stock, M. Wetzler, D. Hoelzer, H. Kantarjian (2010)
Adult acute lymphoblastic leukemiaCancer, 116
-
L. Vidal, A. Gafter-Gvili, G. Salles, M. Dreyling, M. Ghielmini, S. Schmitz, R. Pettengell, M. Witzens‐Harig, O. Shpilberg (2009)
Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.Journal of the National Cancer Institute, 103 23
-
D. Rizzieri, Jeffrey Johnson, J. Byrd, G. Lozanski, B. Powell, T. Shea, Sreenivasa Nattom, E. Hoke, B. Cheson, R. Larson (2010)
Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002Blood, 116
-
R. Kreitman, M. Stetler-Stevenson, I. Margulies, P. Noel, D. FitzGerald, W. Wilson, I. Pastan (2009)
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 18
-
R. Kreitman, I. Pastan (2011)
Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab PasudotoxClinical Cancer Research, 17
-
D. FitzGerald, A. Wayne, R. Kreitman, I. Pastan (2011)
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.Cancer research, 71 20
-
J. Koreth, J. Pidala, W. Pérez, H. Deeg, G. Garcia-Manero, L. Malcovati, M. Cazzola, Sophie Park, R. Itzykson, L. Adès, P. Fenaux, M. Jädersten, E. Hellstrom-Lindberg, R. Gale, C. Beach, P. Greenberg, M. Tallman, J. Dipersio, D. Bunjes, D. Weisdorf, C. Cutler (2011)
A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDSBlood, 118
-
C. Pui, W. Evans (2006)
Treatment of acute lymphoblastic leukemia.The New England journal of medicine, 354 2
-
M. Onda, R. Beers, Laiman Xiang, Byungkook Lee, John Weldon, R. Kreitman, I. Pastan (2011)
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopesProceedings of the National Academy of Sciences, 108
-
T. Lisman, R. Porte (2010)
Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences.Blood, 116 6
-
Stacy Johnson, S. Stevens, S. Woller, Erica Lake, M. Donadini, J. Douketis (2009)
Safety of Excluding Suspected Deep Vein Thrombosis with a Single Whole-Leg Compression Ultrasound: Systematic Review and Meta-Analysis.Blood, 114
-
M. Flowers, B. Storer, Stephanie Lee, P. Campregher, A. Vigorito, P. Carpenter, M. Mielcarek, F. Appelbaum, P. Martin (2009)
Risk Factors for the Development of Acute and National Institute of Health (NIH) Chronic Graft-Versus-Host Disease (GVHD).Blood, 114
-
L. Fayad, H. Patel, G. Verhoef, Mitchell Smith, P. Johnson, M. Czuczman, B. Coiffier, G. Hess, E. Giné, A. Advani, F. Offner, E. Vandendries, M. Shapiro, N. Dang (2008)
Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 StudyBlood, 112
- Publisher
- Springer Journals
- Copyright
- Copyright © 2013 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-013-0160-7
- pmid
- 23539383
- Publisher site
- See Article on Publisher Site
Abstract
The outcomes in adult B-cell acute lymphoblastic leukemia (ALL) remain inferior to those achieved in pediatric populations. Targeted therapy with monoclonal antibodies may improve outcomes in adult B-cell ALL without significant additive toxicity. Rituximab is the best known monoclonal antibody and is routinely used in combination chemo-immunotherapy for treatment of adult B-cell ALL and Burkitts leukemia. A number of other monoclonal antibodies are currently under investigation for treatment of adult B-cell ALL including unconjugated antibodies (eg., ofatumumab, alemtuzumab and epratuzumab), antibodies conjugated to cytotoxic agents (eg., inotuzumab ozogamycin and SAR3419), antibodies conjugated to toxins such Pseudomonas or Diptheria toxins (eg., BL22 and moxetumomab pasudotox), and T-cell engaging bi-specific antibodies that redirect cytotoxic T lymphocytes to lyse target ALL cells (eg., blinatumomab). In this article we review the therapeutic implications, current status and results of monoclonal antibody-based therapy in adult B-cell ALL.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Mar 29, 2013